Screener
Corcept Therapeutics CORT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Long-term operating lease liability | 7,504 | 5,023 |
| Long-term accrued government rebates | 6,132 | 2,562 |
| Long-term accrued income taxes | 15,488 | 15,176 |
| Total liabilities | 182,926 | 188,846 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock | — | — |
| Common stock | 142 | 140 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total liabilities?
- Corcept Therapeutics (CORT) reported total liabilities of $182.93M in Q2 2026.
- How has Corcept Therapeutics's total liabilities changed year-over-year?
- Corcept Therapeutics's total liabilities increased by 10.2% year-over-year, from $165.93M to $182.93M.
- What is the long-term trend for Corcept Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total liabilities has grown at a 31.3% compound annual growth rate (CAGR), from $48.39M to $188.85M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Corcept Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude